Skip to main content

Table 2 Baseline demographic and clinical characteristics of HF, non-HF patients from study group

From: Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure

Characteristics HF patients (n = 9) Non-HF patients (n = 8) P value
Men 6 (66.7%) 7 (87.5%) 0.576
Women 3 (33.3%) 1 (12.5%) 0.576
Age (years) 60.1 ± 14.3 51.8 ± 7.2 0.147
BMI (kg/m2) 26.8 ± 3.1 25.6 ± 1.6 0.323
Hypertension 3 (33.3%) 1 (12.5%) 0.576
Diabetes 2 (22.2%) 1 (12.5%) >0.999
Previous MI 0 (0%) 0 (0%) NA
Smoking 3 (33.3%) 5 (62.5%) 0.347
Hypercholesterolemia 5 (55.6%) 4 (50%) >0.999
AMI 8 (88.9%) 3 (42.9%) 0.106
NT-proBNP (pg/mL)a 918.3 ± 848.5 62 ± 14.1 <0.001
LVEF (%)a 39.3 ± 8.4 66.8 ± 1.9 0.001
Medications
Aspirin 9 (100%) 8 (100%) NA
Clopidogrel 8 (88.9%) 8 (100%) >0.999
Beta blockers 9 (100%) 8 (100%) NA
ACE inhibitors 9 (100%) 8 (100%) NA
Statins 9 (100%) 8 (100%) NA
Diuretics 7 (77.8%) 1 (12.5%) 0.015
  1. aNT-proBNP, LVEF measured 6 months after AMI.
  2. Data are presented as mean value ± standard deviation or number or percentage of patients. P value <0.05 was considered significant.
  3. ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.